Overview

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma